CMS announces rule to restart risk-adjustment payments

On Tuesday, July 24, CMS released a new rule that will allow risk-adjustment payments, which were halted July 7 and threatened to destabilize health insurance marketplaces by keeping billions of dollars from insurers.

“This rule will restore operation of the risk-adjustment program,” CMS Administrator Seema Verma, MPH, said in a statement. “Issuers that had expressed concerns about having to withdraw from markets or becoming insolvent should be assured by our actions today. Alleviating concerns in the market helps to protect consumer choices.”   

The payments, which do not include public money, transfer funds from insurers who cover healthier populations to those with sicker customers. The program, which amounted to $10.4 billion in payments in 2017, is designed to ensure insurers do not select healthier patients.

America’s Health Insurance Plans, the largest health insurance lobbying group, criticized the initial move to halt payments, while encouraging the Trump administration to quickly address the situation to minimize disruption in the insurance marketplaces.

“We agree that a quick resolution is needed to avoid greater harm to the individual and small group markets,” the group said in a prepared statement. “More than ever, American businesses and families want affordable coverage and care they need and deserve. We encourage the administration to reevaluate its decision and work with all stakeholders to make health care more affordable for all Americans."

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.